Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.63 · Expires 2036-05-11 | Direct | 10,958 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,958 · Balance 10,958 F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 20:55 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 10,958 | $0.00 Strike: $24.63 | $0.00 |
DisclosureSEC source: 0002008499-26-000005 · wk-form4_1778792156.xml · derivative · entry 1 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,958 Underlying: Common Stock · 10,958 shares Expires 2036-05-11 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 5,243 | $11.82 Strike: $16.59 | $61,972.26 |
DisclosureSEC source: 0002008499-26-000002 · wk-form4_1767736064.xml · derivative · entry 1 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,243 Underlying: Common Stock · 5,243 shares Expires 2036-01-01 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $62,000. F1 · derivative.exercise_date: 1,311 shares underlying the option shall vest on March 31, 2026, 1,311 shares underlying the option shall vest on June 30, 2026, 1,310 shares underlying the option shall vest on September 30, 2026 and 1,311 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:16 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 15,287 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001999480-25-000038 · wk-form4_1747340169.xml · derivative · entry 1 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,287 Underlying: Common Stock · 15,287 shares Expires 2035-05-12 F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:18 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 19,558 | $3.17 Strike: $4.38 | $61,998.86 |
DisclosureSEC source: 0001999480-25-000006 · wk-form4_1736198292.xml · derivative · entry 1 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,558 Underlying: Common Stock · 19,558 shares Expires 2035-01-01 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $62,000. F1 · derivative.exercise_date: 4,889 shares underlying the option shall vest on March 31, 2025, 4,890 shares underlying the option shall vest on June 30, 2025, 4,889 shares underlying the option shall vest on September 30, 2025 and 4,890 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:41 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries A Preferred Stock · Derivative | 53,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002942 · form4-02072024_090216.xml · derivative · entry 2 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:41 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 23,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002942 · form4-02072024_090216.xml · nonDerivative · entry 1 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:47 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 3,083 | $11.88 Strike: $16.00 | $36,638.37 |
DisclosureSEC source: 0001415889-24-002570 · form4-02052024_090213.xml · derivative · entry 2 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,083 Underlying: Common Stock · 3,083 shares Expires 2034-01-31 F3 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $36,667. F2 · derivative.exercise_date: 560 shares underlying the option shall vest on March 31, 2024, and 841 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:47 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 30,574 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002570 · form4-02052024_090213.xml · derivative · entry 1 York Gwill · CIK 0002008499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 30,574 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on March 1, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.